Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
Annals of Oncology, Volume 17, No. 6, Year 2006
Notification
URL copied to clipboard!
Description
Background: We sought to determine whether a high-risk group could be defined among patients with operable breast cancer in whom a search of occult central nervous system (CNS) metastases was justified. Patients and methods: We evaluated data from 9524 women with early breast cancer (42% node-negative) who were randomized in International Breast Cancer Study Group clinical trials between 1978 and 1999, and treated without anthracyclines, taxanes, or trastuzumab. We identified patients whose site of first event was CNS and those who had a CNS event at any time. Results: Median follow-up was 13 years. The 10-year incidence (10-yr) of CNS relapse was 5.2% (1.3% as first recurrence). Factors predictive of CNS as first recurrence included: node-positive disease (10-yr = 2.2% for > 3 N+), estrogen receptor-negative (2.3%), tumor size > 2 cm (1.7%), tumor grade 3 (2.0%), < 35 years old (2.2%), HER2-positive (2.7%), and estrogen receptor-negative and node-positive (2.6%). The risk of subsequent CNS recurrence was elevated in patients experiencing lung metastases (10-yr = 16.4%). Conclusion: Based on this large cohort we were able to define risk factors for CNS metastases, but could not define a group at sufficient risk to justify routine screening for occult CNS metastases. © 2006 Oxford University Press.
Authors & Co-Authors
Pestalozzi, Bernhard Cornelius
Unknown Affiliation
Zahrieh, David M.
Unknown Affiliation
Price, Karen N.
Unknown Affiliation
Holmberg, Stig B.
Unknown Affiliation
Lindtner, Jurij
Unknown Affiliation
Collins, John Paxton
Unknown Affiliation
Crivellari, Diana
Unknown Affiliation
Fey, Martin F.
Unknown Affiliation
Murray, Elizabeth M.
Unknown Affiliation
Pagani, O.
Unknown Affiliation
Simoncini, Edda Lucia
Unknown Affiliation
Castiglione-Gertsch, Monica
Unknown Affiliation
Gelber, Richard D.
Unknown Affiliation
Coates, Alan S.
Unknown Affiliation
Goldhirsch, Aaron
Unknown Affiliation
Statistics
Citations: 391
Authors: 15
Affiliations: 15
Identifiers
Doi:
10.1093/annonc/mdl064
ISSN:
09237534
e-ISSN:
15698041
Research Areas
Cancer
Study Design
Cohort Study
Participants Gender
Female